相关实验视频

Updated: May 5, 2026

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release

Published on: February 13, 2016

稳定氧化:MnFe₂O₄@Cap-SNO纳米颗粒和奇托桑水凝用于受控的治疗输送

Soodabeh Gharibeh¹, Melika JaberebnAnsari², Elham Askarizadeh²

¹Department of Science, Fi.C., Islamic Azad University, Firoozkooh, Iran.

Nitric oxide : biology and chemistry

|November 8, 2025

概括

研究人员开发了新的纳米粒子和水凝系统来稳定氧化 (NO) 以提高药物输送. MnFe2O4@Cap-SNO纳米颗粒显示出优异的NO稳定性和持续释放,表明生物医学应用的潜力.

科学领域:

生物材料科学生物材料科学
纳米技术纳米技术
药物输送系统药物输送系统

背景情况:

氧化 (NO) 是至关重要的,但不稳定,限制其治疗用途.
开发稳定的NO输送系统对于生物医学应用至关重要.
卡普托普利 (Cap) 可以作为一氧化 (NO) 捐赠剂.

研究的目的:

合成和表征新的纳米粒子和水凝系统,以提高氧化 (NO) 的稳定性和可控释放.
评估开发系统的NO释放动力学和稳定性.
评估这些系统在向药物输送方面的潜力.

主要方法:

合成了MnFe2O4@Cap-SNO纳米粒子和Cs@Cap-SNO水凝.
使用UV-Vis光谱光度测定来确认化.
评估NO释放概况和动力学 (零级和科尔斯迈耶-佩帕斯).
对NO的保存进行的比较稳定性研究.

主要成果:

成功合成了MnFe2O4@Cap-SNO纳米粒子和Cs@Cap-SNO水凝.
紫外线Vis证实了在335nm和545nm的吸收带的化.
MnFe2O4@Cap-SNO显示持续NO释放时间高达16h (零级动力学).
Cs@Cap-SNO显示NO释放的速度更快 (Korsmeyer-Peppas动力学).
与Cs@Cap-SNO和自由的Cap-SNO相比,MnFe2O4@Cap-SNO表现出更高的NO稳定性.

结论:

MnFe2O4@Cap-SNO纳米粒子是稳定氧化 (NO) 的有效载体.
这些纳米颗粒提供了持续的NO释放,适合于向药物输送.
需要进一步的体外和体内研究来验证治疗疗效.

关键词:

生物医学应用生物医学应用有控制的药物释放.MnFe(2)O(4)@Cap-SNO纳米颗粒的使用方法没有 NO 稳定.氧化氧化是什么?

更多相关视频

Manganese Oxide Nanoparticle Synthesis by Thermal Decomposition of ManganeseII Acetylacetonate

Manganese Oxide Nanoparticle Synthesis by Thermal Decomposition of ManganeseII Acetylacetonate

Published on: June 18, 2020

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

相关概念视频

Nitric Oxide Signaling Pathway

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...